By Fineline Cube China’s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for the 2026 medical insurance catalog adjustment, revealing that 601 out of 664 generic drug names (91% pass rate) successfully advanced to the next stage of evaluation.
Review Process Overview
| Component | Basic Medical Insurance Catalog | Commercial Insurance Innovative Drug Catalog |
|---|---|---|
| Total Submissions | 800 submissions | 62 submissions |
| Generic Drug Names | 664 | 62 |
| Passed Formal Review | 601 (91% pass rate) | 58 (94% pass rate) |
| Outside Current Catalog | 368 | 57 |
| Within Current Catalog | 233 | 1 |
| Public Feedback Received | 103 pieces (combined) | |
| Drug Names Updated | 15 generic drug names |
Strategic Implications for Pharmaceutical Industry
High Pass Rates Signal Streamlined Process
- 91% basic catalog pass rate indicates NHSA has refined its formal review criteria, reducing administrative barriers for eligible products
- 94% commercial innovative drug catalog pass rate demonstrates strong government support for novel therapeutics in supplementary insurance coverage
- Efficiency improvements likely reflect lessons learned from previous annual negotiations and catalog adjustments
Market Access Opportunities
- 368 new drugs outside current catalog represent significant commercial opportunity for manufacturers seeking first-time reimbursement
- 233 existing catalog drugs undergoing re-evaluation may face price renegotiation or indication-specific coverage changes
- Commercial insurance pathway provides alternative access route for innovative drugs that may not meet basic catalog cost-effectiveness thresholds
Public Feedback & Quality Control
- 103 public comments received during feedback period demonstrate stakeholder engagement in transparent process
- 15 generic drug names updated following re-examination shows NHSA’s commitment to accuracy and responsiveness
- Correction mechanism provides safety net for administrative errors while maintaining overall process integrity
The NHSA’s annual catalog adjustment represents one of the world’s largest pharmaceutical pricing and reimbursement exercises, directly impacting market access for thousands of products serving China’s 1.4 billion population.
Commercial Impact & Forward Outlook
- Timeline Expectations: Final catalog decisions typically announced by year-end, with implementation effective January 1, 2027
- Negotiation Phase: Drugs passing formal review now enter confidential price negotiations with NHSA
- Market Dynamics: High pass rates may intensify competition among similar products, potentially driving steeper price concessions
- Innovation Incentives: Dual-track approach (basic + commercial catalogs) creates tiered access system supporting both cost containment and innovation adoption
- Industry Strategy: Manufacturers must prepare robust health economics data and flexible pricing strategies for upcoming negotiations
Forward‑Looking Statements
This brief contains forward‑looking statements regarding NHSA catalog inclusion, pricing negotiations, and market access outcomes. Actual results may differ due to risks including final regulatory decisions, competitive dynamics, and evolving healthcare policy priorities.-Fineline Info & Tech